Indication
Aplastic anemia
Aplastic anemia is a rare and life-threatening hematologic disorder marked by bone marrow failure and profound peripheral pancytopenia. Read more about Aplastic anemia
21 drugs 18 manufacturers
Drugs that treat it
Common Aplastic anemia therapies.
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
PROMACTA (eltrombopag olamine)
ELTROMBOPAG OLAMINE
ELTROMBOPAG OLAMINE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAplastic anemia is a rare and life-threatening hematologic disorder marked by bone marrow failure and profound peripheral pancytopenia.
It affects the hematopoietic system across all age groups and typically arises from immune-mediated destruction of hematopoietic stem and progenitor cells by autoreactive cytotoxic T lymphocytes, though it may also develop secondary to inherited genetic syndromes, toxic exposures, radiation, or viral infections.
The hallmark pathophysiology involves severe bone marrow hypocellularity, where fatty tissue replaces functional marrow elements, clinically manifesting as fatigue and pallor from anemia, increased susceptibility to severe infections from neutropenia, and mucocutaneous bleeding or petechiae due to thrombocytopenia.
- nih.gov
Aplastic anemia is a rare and life-threatening hematologic disorder marked by bone marrow failure and profound peripheral pancytopenia The hallmark pathophysiology involves severe bone marrow hypocellularity, where fatty tissue replaces functional marrow elements, clinically manifesting as fatigue and pallor from anemia, increased susceptibility to severe infections from neutropenia, and mucocutaneous bleeding or petechiae due to thrombocytopenia
- nih.gov
Aplastic anemia is a rare and life-threatening hematologic disorder marked by bone marrow failure and profound peripheral pancytopenia The hallmark pathophysiology involves severe bone marrow hypocellularity, where fatty tissue replaces functional marrow elements, clinically manifesting as fatigue and pallor from anemia, increased susceptibility to severe infections from neutropenia, and mucocutaneous bleeding or petechiae due to thrombocytopenia
- nih.gov
It affects the hematopoietic system across all age groups and typically arises from immune-mediated destruction of hematopoietic stem and progenitor cells by autoreactive cytotoxic T lymphocytes, though it may also develop secondary to inherited genetic syndromes, toxic exposures, radiation, or viral infections The hallmark pathophysiology involves severe bone marrow hypocellularity, where fatty tissue replaces functional marrow elements, clinically manifesting as fatigue and pallor from anemia,...
- nih.gov
It affects the hematopoietic system across all age groups and typically arises from immune-mediated destruction of hematopoietic stem and progenitor cells by autoreactive cytotoxic T lymphocytes, though it may also develop secondary to inherited genetic syndromes, toxic exposures, radiation, or viral infections
Personalize your experience
Follow Aplastic anemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.